The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.
Susan M. Hiniker
No relevant relationships to disclose
Erqi L. Pollom
No relevant relationships to disclose
Michael S. Khodadoust
No relevant relationships to disclose
Margaret M. Kozak
No relevant relationships to disclose
Ranjana H. Advani
No relevant relationships to disclose
Richard T. Hoppe
No relevant relationships to disclose